JP2025102768A5 - - Google Patents
Info
- Publication number
- JP2025102768A5 JP2025102768A5 JP2025033734A JP2025033734A JP2025102768A5 JP 2025102768 A5 JP2025102768 A5 JP 2025102768A5 JP 2025033734 A JP2025033734 A JP 2025033734A JP 2025033734 A JP2025033734 A JP 2025033734A JP 2025102768 A5 JP2025102768 A5 JP 2025102768A5
- Authority
- JP
- Japan
- Prior art keywords
- hbv
- gene
- cas9
- domain
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962846422P | 2019-05-10 | 2019-05-10 | |
| US62/846,422 | 2019-05-10 | ||
| US201962927585P | 2019-10-29 | 2019-10-29 | |
| US62/927,585 | 2019-10-29 | ||
| PCT/US2020/032226 WO2020231863A1 (en) | 2019-05-10 | 2020-05-08 | Compositions and methods for treating hepatitis b |
| JP2021566276A JP7679309B2 (ja) | 2019-05-10 | 2020-05-08 | Ｂ型肝炎を治療するための組成物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566276A Division JP7679309B2 (ja) | 2019-05-10 | 2020-05-08 | Ｂ型肝炎を治療するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025102768A JP2025102768A (ja) | 2025-07-08 |
| JP2025102768A5 true JP2025102768A5 (enExample) | 2025-08-13 |
Family
ID=73289231
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566276A Active JP7679309B2 (ja) | 2019-05-10 | 2020-05-08 | Ｂ型肝炎を治療するための組成物及び方法 |
| JP2025033734A Pending JP2025102768A (ja) | 2019-05-10 | 2025-03-04 | Ｂ型肝炎を治療するための組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566276A Active JP7679309B2 (ja) | 2019-05-10 | 2020-05-08 | Ｂ型肝炎を治療するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230070861A1 (enExample) |
| EP (1) | EP3965832A4 (enExample) |
| JP (2) | JP7679309B2 (enExample) |
| KR (1) | KR20220019685A (enExample) |
| CN (2) | CN114929287B (enExample) |
| AU (1) | AU2020276218A1 (enExample) |
| CA (1) | CA3139324A1 (enExample) |
| WO (1) | WO2020231863A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12529041B2 (en) | 2018-09-07 | 2026-01-20 | Beam Therapeutics Inc. | Compositions and methods for delivering a nucleobase editing system |
| WO2021222318A1 (en) | 2020-04-28 | 2021-11-04 | The Broad Institute, Inc. | Targeted base editing of the ush2a gene |
| AU2022216614B2 (en) | 2021-02-05 | 2026-03-05 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| US20240150413A1 (en) * | 2021-03-12 | 2024-05-09 | Massachusetts Institute Of Technology | Compositions and methods for dominant antiviral therapy |
| WO2023004375A2 (en) * | 2021-07-22 | 2023-01-26 | Emendobio Inc. | Hepatitis b virus (hbv) knockouts |
| KR20240111821A (ko) * | 2021-09-27 | 2024-07-17 | 빔 테라퓨틱스, 인크. | B형 간염 바이러스 감염을 치료하기 위한 조성물 및 방법 |
| WO2024103051A2 (en) * | 2022-11-11 | 2024-05-16 | The United States Government As Represented By The Department Of Veterans Affairs | Hiv specific exosomes and uses thereof |
| WO2024186890A1 (en) * | 2023-03-06 | 2024-09-12 | Intellia Therapeutics, Inc. | Compositions and methods for hepatitis b virus (hbv) genome editing |
| EP4713453A1 (en) | 2023-05-15 | 2026-03-25 | nChroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240172759A (ko) * | 2013-06-17 | 2024-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 간의 표적화 및 치료를 위한 ＣＲＩＳＰＲＣａｓ 시스템, 벡터 및 조성물의 전달 및 용도 |
| CN105899658B (zh) * | 2013-12-12 | 2020-02-18 | 布罗德研究所有限公司 | 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用 |
| EP3365447A1 (en) * | 2015-10-21 | 2018-08-29 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating hepatitis b virus |
| JP7231935B2 (ja) * | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| CN110520163A (zh) * | 2017-01-05 | 2019-11-29 | 新泽西鲁特格斯州立大学 | 独立于dna双链断裂的靶向基因编辑平台及其用途 |
| WO2019005886A1 (en) * | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS |
| US11732274B2 (en) * | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
-
2020
- 2020-05-08 US US17/610,119 patent/US20230070861A1/en active Pending
- 2020-05-08 CA CA3139324A patent/CA3139324A1/en active Pending
- 2020-05-08 AU AU2020276218A patent/AU2020276218A1/en active Pending
- 2020-05-08 WO PCT/US2020/032226 patent/WO2020231863A1/en not_active Ceased
- 2020-05-08 CN CN202080050214.3A patent/CN114929287B/zh active Active
- 2020-05-08 JP JP2021566276A patent/JP7679309B2/ja active Active
- 2020-05-08 KR KR1020217039921A patent/KR20220019685A/ko active Pending
- 2020-05-08 CN CN202510594053.9A patent/CN120586100A/zh active Pending
- 2020-05-08 EP EP20806106.9A patent/EP3965832A4/en active Pending
-
2025
- 2025-03-04 JP JP2025033734A patent/JP2025102768A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025102768A5 (enExample) | ||
| JP2025120176A5 (enExample) | ||
| JP2025170240A5 (enExample) | ||
| CN112534054B (zh) | 使用可编程碱基编辑器系统取代病原性氨基酸的方法 | |
| CN112601816B (zh) | 使用可编程碱基编辑器系统遏止病原性突变的方法 | |
| JPWO2021050571A5 (enExample) | ||
| KR100379569B1 (ko) | 개기원의아데노바이러스벡터및유전자치료에서이의사용방법 | |
| US20210261938A1 (en) | Evolution of cytidine deaminases | |
| JP2024038327A5 (enExample) | ||
| JP2019536425A5 (enExample) | ||
| JPWO2019217943A5 (enExample) | ||
| CN118420784A (zh) | 用于提高碱基编辑精度的融合蛋白 | |
| JP2020510439A5 (enExample) | ||
| WO2017070284A1 (en) | Crispr/cas-related methods and compositions for treating hepatitis b virus | |
| JPWO2019217944A5 (enExample) | ||
| JP2020510426A (ja) | 翻訳可能分子およびその合成 | |
| Zhou et al. | Efficient silencing of hepatitis B virus S gene through CRISPR‐mediated base editing | |
| JPWO2020231863A5 (enExample) | ||
| JPWO2021102390A5 (enExample) | ||
| JPWO2020236936A5 (enExample) | ||
| JPWO2022125968A5 (enExample) | ||
| JPWO2021041885A5 (enExample) | ||
| JPWO2023039447A5 (enExample) | ||
| CN118599013A (zh) | 一种具有胞嘧啶脱氨功能的融合蛋白及其应用 | |
| CN115247162B (zh) | 一种腺嘌呤碱基编辑用融合蛋白及其应用 |